Merck & Co Inc (NYSE:MRK)
| 72.54 BATS BZX Real-Time Price As of 11:06am ET |  -0.31 / -0.43%Today’s Change | 65.25 Today|||52-Week Range 87.80 | -11.32% Year-to-Date |
Latest MRK News | Press Releases
| Stock Market News for Mar 3, 2021 9:31am / Zacks.com - Paid Partner Content | Merck to Assist J&J Vaccine; Target Beats in Q4 Mar 02 / Zacks.com - Paid Partner Content |
| Merck (MRK) to Help J&J Make COVID-19 Vaccine to Boost Supply 7:20am / Zacks.com - Paid Partner Content | Where Will Pfizer Be in 1 Year? Mar 02 / MotleyFool.com - Paid Partner Content |
| AstraZeneca Just Sold Its Moderna Stock: Should You? 6:04am / MotleyFool.com - Paid Partner Content | Hillman Capital's Top 4 Buys of the 4th Quarter Feb 26 / GuruFocus News - Paid Partner Content |
| Market Mood Swings: Buffett's Berkshire Reports 2020 Annual Earnings Mar 02 / GuruFocus News - Paid Partner Content | Buy This Blue Chip on the Dip Feb 26 / MotleyFool.com - Paid Partner Content |
| Wall Street Starts a Fresh Week at Record Highs Mar 02 / Zacks.com - Paid Partner Content | Iovance (IOVA) Q4 Earnings Miss Estimates, Pipeline in Focus Feb 26 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 72.85 |
| Today’s open | 72.83 |
| Day’s range | 72.42 - 73.43 |
| Volume | 4,208,051 |
| Average volume (3 months) | 9,632,639 |
| Market cap | $183.8B |
Data as of 11:06am ET, 03/03/2021
Growth & Valuation
| Earnings growth (last year) | -27.21% |
| Earnings growth (this year) | +9.09% |
| Earnings growth (next 5 years) | +8.00% |
| Revenue growth (last year) | +3.06% |
| P/E ratio | 26.1 |
| Price/Sales | 4.33 |
| Price/Book | 7.26 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| PFEPfizer | +0.36 | +1.07% |
| ABBVAbbVie | -2.21 | -2.05% |
| LLYEli Lilly and Co | -3.19 | -1.56% |
| NVSNovartis | -0.86 | -0.98% |
Data as of 11:06am ET, 03/03/2021
Financials
| Next reporting date | April 29, 2021 |
| EPS forecast (this quarter) | $1.63 |
| Annual revenue (last year) | $48.0B |
| Annual profit (last year) | $7.1B |
| Net profit margin | 14.72% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Kenilworth, New Jersey |
Forecasts
